Business Context and Reporting Period
This Form 8-K Current Report was filed by Context Therapeutics Inc. on November 5, 2025. The filing serves to disclose the Company's third quarter 2025 operating and financial results via a press release (Exhibit 99.2) and provides updates on its clinical trial pipeline (Item 8.01). Context Therapeutics is an emerging growth company focused on developing bispecific T cell engagers (TCEs).
Key Financial Metrics
The filing text references the issuance of third quarter 2025 financial results but does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached press release (Exhibit 99.2) and corporate presentation (Exhibit 99.1), which are incorporated by reference but not detailed in the body of this 8-K.
Material Changes and Clinical Updates
The primary material updates concern the progress of three clinical candidates:
- CTIM-76 (CLDN6 x CD3): In Phase 1 dose escalation for ovarian, endometrial, or testicular cancer. As of October 30, 2025, 12 patients were enrolled. The study is currently enrolling Cohort 5 (140 mcg priming, 560 mcg full dose). Preliminary anti-tumor activity (RECIST response) was observed starting at Cohort 3. No Cytokine Release Syndrome (CRS) greater than Grade 1 or dose-limiting toxicity (DLT) has been observed; maximum tolerated dose (MTD) has not been reached.
- CT-95 (MSLN x CD3): In Phase 1 dose escalation for pancreatic, non-small cell lung, ovarian, mesothelioma, and colorectal cancer. As of October 30, 2025, 6 patients were enrolled. The study is currently enrolling Cohort 3 (0.18 mcg/kg priming, 0.6 mcg/kg full dose). Target dose exposure is projected at Cohort 4. No CRS greater than Grade 2 or DLT has been observed; MTD has not been reached.
- CT-202 (Nectin-4 x CD3): In preclinical development for bladder, non-small cell lung, colorectal, breast, and head and neck cancer.
Guidance, Outlook, and Risks
Management provided the following timeline and outlook:
- CTIM-76: The Company anticipates providing updated interim Phase 1a data and Phase 1b dose selection in the second quarter of 2026. The goal is to deepen RECIST responses while maintaining a favorable safety profile.
- CT-95: The Company anticipates providing initial Phase 1a data in the middle of 2026.
- CT-202: The Company expects to complete regulatory filings to support the initiation of a first-in-human trial in the second quarter of 2026.
- Risks: While no specific risks are detailed in the text of this 8-K, the Company notes that MTD has not been reached for CTIM-76 or CT-95, implying ongoing uncertainty regarding final dosing and safety profiles.
Investor Verification Checklist
- Review Exhibit 99.2 (Press Release) for specific Q3 2025 revenue, cash burn, and liquidity figures, as these are not present in the 8-K text.
- Verify the specific nature of the "ongoing RECIST response" mentioned for CTIM-76 in the full press release or corporate presentation.
- Confirm the timeline for the initiation of the CT-202 first-in-human trial against the Q2 2026 guidance.
- Monitor upcoming data releases in Q2 2026 for CTIM-76 and mid-2026 for CT-95 to validate the projected safety and efficacy profiles.